Business
Kezar Life Sciences Announces Presentations of Four Abstracts at the 2019 ACR/ARP Annual Meeting
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and
About this update from Kezar Life Sciences, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced four poster presentations at the upcoming 2019 ACR/ARP Annual Meeting taking place from November 8-13, 2019 in Atlanta, GA. \n “The selection of four abstracts featuring data with our first-in-class selective immunoproteasome inhibitor, KZR-616, underscores Kezar’s unique ability to translate novel science into viable treatment options for patients living with severe autoimmune diseases,” said Christopher Kirk, PhD, Kezar’s President and Chief Scientific Officer. “We’re thrilled to highlight the growing body of data supporting KZR-616’s favorable risk/benefit profile and its potential to treat a number of these debilitating and underserved diseases.” Summarized below are the abstract titles that have been selected for poster presentations. The abstracts are available online on the conference website. Additional details will be presented at the meeting and are under embargo until November 9, 2019 at 4:30 PM (ET). All poster presentations will also be made available on the Company’s investor relations site following the conference. Abstract Number 85: Selective Inhibition of the Immunoproteasome with KZR-616 Blocks Multiple Cell Signaling Pathways, Plasma Cell Signatures and Myeloid Cell Associated Damage in the NZB/W Lupus Nephritis ModelDate: Sunday, November 10, 2019Time: 9:00am – 11:00amPoster Session: SLE – Animal Models Abstract Number 2520: Treatment of SLE Patients with the Immunoproteasome Inhibitor KZR-616: Results from the First 3 Cohorts of an Open-Label Phase 1b Dose Escalation TrialDate: Tuesday, November 12, 2019Time: 9:00am – 11:00am Poster Session: SLE – Clinical Poster III: Treatment Abstract Number 2528: Profiling of Gene Expression, Immune Cell Subtypes, and Circulating Protein Biomarkers in Systemic Lupus Erythematosus Patients Treated with the Selective Immunoproteasome Inhibitor, KZR-616Date: Tuesday, November 12, 2019Time: 9:00am – 11:00am Poster Session: SLE – Clinical Poster III: Treatment Abstract Number 2530: Safety, Pharmacokinetics, and Pharmacodynamics of a Lyophilized Drug Product of KZR-616, a Selective Inhibitor of the Immunoproteaso...